Soteria Biotherapeutics

Soteria Biotherapeutics is a private immuno-oncology company focused on developing the next generation of switchable bispecific T-cell engagers for the treatment of patients with solid tumors. Soteria's highly innovative T-LITE™ platform enables small molecule-dependent activation of bispecific antibody therapies, achieving safer and more effective treatments through tunable activity, reduced side effects, and higher dosing. Our mission is to safely harness the body’s natural immune system to fight cancer and transform patients’ lives. The company was founded in 2018 by renowned protein engineer Dr. Jim Wells, Dr. Zachary Hill, and Dr. Alexander Martinko from the University of California, San Francisco.